CTOs on the Move

PopperSwift

www.popperswift.com

 
PopperSwift is a New Canaan, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Cool Springs Psychiatric Group

Cool Springs Psychiatric Group is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vets First Choice

We are the nation`s largest veterinary partner-pharmacy providing veterinarians with a custom online store so they can offer the best home delivery service for their clients. We offer pet owners a way to shop online with their own veterinarian in a safe and secure web store for their pet. Behind the scenes, we are the veterinarian`s fully-licensed and accredited veterinary pharmacy. We have direct partnerships with all of the manufacturers--so we don`t just guarantee that the products “are the same”...we 100% guarantee that all products have been handled properly to maintain their quality. That`s a big difference when it comes to the safety of a pet.

CALSTAR, California Shock Trauma Air Rescue

CALSTAR, California Shock Trauma Air Rescue is a Mcclellan, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MECA - Medical Equipment Compliance Associates

MECA - Medical Equipment Compliance Associates is a Franklin, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.